

## **'Completely new' COVID strains possible** this winter: EU

2 September 2022



Credit: Pixabay/CC0 Public Domain

Entirely new COVID variants could emerge this winter but existing vaccines should protect people from serious illness and death, the EU's drug agency said on Friday.

The comments came as the 27-nation European Union prepares to roll out a booster campaign ahead of a feared wave of new coronavirus cases later this year.

It will include a mix of newly-approved jabs adapted for the now dominant Omicron strain, and the original vaccines developed to fight the virus that first emerged in China in 2019, the European Medicines Agency (EMA) said.

But people "should not wait for a specific <u>vaccine</u>", EMA vaccines chief Marco Cavaleri told a news conference.

"There might be a completely new <u>variant</u> emerging that we are not able to predict today."

On Thursday, the EMA approved vaccines by Pfizer/BioNTech and Moderna that are adapted to tackle the older BA.1 subvariant of Omicron.

A Pfizer version updated for the now-dominant BA.4 and 5 strains should be authorised in mid-September, while a similar Moderna jab is also in the pipeline.

But these new Omicron-adapted jabs will largely be reserved for boosters for the elderly, the vulnerable, <u>pregnant women</u> and <u>healthcare workers</u>, Cavaleri said.

Most people will instead still get the original vaccines that are designed to tackle the Wuhan strain of coronavirus.

"The original vaccines are still able to protect against severe COVID 19 disease and death", even if they are less effective at preventing infection.

He said it was "not excluded" that new variants this winter might end up being closer to earlier Omicron strains that had now largely been overtaken by the BA.4 and 5 types.

© 2022 AFP



APA citation: 'Completely new' COVID strains possible this winter: EU (2022, September 2) retrieved 14 September 2022 from <u>https://medicalxpress.com/news/2022-09-covid-strains-winter-eu.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.